AMD/Retina Edition: Top Headlines for Week of July 18, 2022

In this edition, Iveric Bio is given exclusive permission to develop, commercialize new formulations of Zimura; subretinal drusenoid deposits linked with cardiovascular disease; subcutaneous elamipretide may improve visual function in geographic atrophy; and more.

Read the full coverage here:

Iveric Bio given exclusive permission to develop, commercialize new formulations of Zimura

Subretinal drusenoid deposits linked with cardiovascular disease

Subcutaneous elamipretide may improve visual function in geographic atrophy

Combination technique useful for treating myopic traction maculopathy

Insufficient treatment common among patients with wet AMD

References:

Barikian A, et al. Characteristics and outcomes of patients with nAMD managed in US routine clinical practice: An analysis of the IRIS Registry database. Presented at: American Society of Retina Specialists annual meeting; July 13-16, 2022; New York.

Chew FM, et al. Scleral imbrication with combined pars plana vitrectomy and foveal sparing ILM peel as a useful surgical modality in treating myopic traction maculopathy. Presented at: American Society of Retina Specialists annual meeting; July 13-16, 2022; New York.

Heier JS. ReCLAIM-2 study results: A phase 2 study of elamipretide safety & efficacy in geographic atrophy. Presented at: American Society of Retina Specialists annual meeting; July 13-16, 2022; New York.

Press Release

Thompson RJ, et al. Retina. 2022;doi:10.1097/IAE.0000000000003460.